129 related articles for article (PubMed ID: 38142326)
1. New-onset Blepharitis and Anti-TNF-Alpha Therapy in Patients with Crohn's Disease: A Case Series and Literature Review.
Weintraub Y; Lev-Tzion R; Ollech J; Olshaker H; Rosen I; Cohen S; Varssano D; Shouval DS; Matar M
Isr Med Assoc J; 2023 Dec; 25(12):836-840. PubMed ID: 38142326
[No Abstract] [Full Text] [Related]
2. Pustular lesions in patients with Crohn disease and treatment with tumour necrosis factor-α inhibitors.
Balaguer-Franch I; Hernández de la Torre-Ruiz E; Lacasta-Plasin C; García-Piqueras P; Menchén-Viso L; Baniandrés-Rodríguez O
Clin Exp Dermatol; 2022 Feb; 47(2):453-455. PubMed ID: 34431537
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF Rechallenge After Infliximab Induced Lupus in Crohn's Disease.
Loebenstein M; Schulberg JD
Gastroenterology; 2020 Jun; 158(8):2069-2071. PubMed ID: 31945355
[No Abstract] [Full Text] [Related]
4. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
Clark-Snustad KD; Singla A; Lee SD
Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
[TBL] [Abstract][Full Text] [Related]
5. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
6. Association of Blepharitis and Ectropion With Tumor Necrosis Factor α Inhibitor Treatment in Crohn Disease.
Teo HMT; de Sá Freire F; Demirci H
JAMA Ophthalmol; 2019 Feb; 137(2):232-233. PubMed ID: 30419086
[No Abstract] [Full Text] [Related]
7. Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery.
Dai C; Huang YH
Dig Dis Sci; 2022 Apr; 67(4):1421-1422. PubMed ID: 33939139
[No Abstract] [Full Text] [Related]
8. Infliximab
Kim ES; Kang B
World J Gastroenterol; 2023 May; 29(18):2784-2797. PubMed ID: 37274072
[TBL] [Abstract][Full Text] [Related]
9. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW
Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638
[TBL] [Abstract][Full Text] [Related]
10. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
Ding NS; McDonald JAK; Perdones-Montero A; Rees DN; Adegbola SO; Misra R; Hendy P; Penez L; Marchesi JR; Holmes E; Sarafian MH; Hart AL
J Crohns Colitis; 2020 Sep; 14(8):1090-1102. PubMed ID: 32119090
[TBL] [Abstract][Full Text] [Related]
11. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
[TBL] [Abstract][Full Text] [Related]
12. Persistent Constitutional Symptoms and Cholestasis During Anti-TNF Therapy as a Harbinger of a Surprising Condition.
Fonseca Chebli JM; Akkari Evangelista RK; Chebli LA
Gastroenterology; 2024 Feb; 166(2):e1-e4. PubMed ID: 37490972
[No Abstract] [Full Text] [Related]
13. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
14. De novo Anti-TNF-α-induced Congestive Heart Failure in a Patient With Turner Syndrome and Crohn's Disease.
Keating E; Kelleher TB; Lahiff C
Inflamm Bowel Dis; 2020 Nov; 26(12):e161-e162. PubMed ID: 32619005
[No Abstract] [Full Text] [Related]
15. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
16. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
18. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
Eriksson C; Söderling J; Karlqvist S; Bröms G; Everhov ÅH; Bergemalm D; Ludvigsson JF; ; Olén O; Halfvarson J
Dig Dis Sci; 2023 Jul; 68(7):3119-3128. PubMed ID: 36929241
[TBL] [Abstract][Full Text] [Related]
19. [IgA vasculitis associated with anti-TNF-α inhibitors in a patient with Crohn's disease].
Nishikawa J; Hosokawa A; Akashi M; Mihara H; Nanjo S; Yoshita H; Ando T; Kajiura S; Fujinami H; Sugiyama T
Nihon Shokakibyo Gakkai Zasshi; 2015 Oct; 112(10):1852-7. PubMed ID: 26440688
[TBL] [Abstract][Full Text] [Related]
20. Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab.
Powell Doherty RD; Liao H; Satsangi JJ; Ternette N
Gastroenterology; 2020 Aug; 159(2):784-787. PubMed ID: 32275970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
